FIDVAXI Trademark

Trademark Overview


On Thursday, September 1, 2022, a trademark application was filed for FIDVAXI with the United States Patent and Trademark Office. The USPTO has given the FIDVAXI trademark a serial number of 79352782. The federal status of this trademark filing is REGISTERED as of Tuesday, November 21, 2023. This trademark is owned by Genexine, Inc.. The FIDVAXI trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of vaccines and medicines; development of new cell therapy products for others; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; Pharmaceutical drug development services; inspection of pharmaceuticals; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; research on the subject of pharmaceuticals; clinical research in the field of medicine; consultancy pertaining to pharmacology; medical laboratories; medical research laboratory services; medical research laboratory services for predicting disease; medicine research; testing of pharmaceuticals
fidvaxi

General Information


Serial Number79352782
Word MarkFIDVAXI
Filing DateThursday, September 1, 2022
Status700 - REGISTERED
Status DateTuesday, November 21, 2023
Registration Number7220670
Registration DateTuesday, November 21, 2023
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, September 5, 2023

Trademark Statements


Goods and ServicesResearch and development of vaccines and medicines; development of new cell therapy products for others; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; Pharmaceutical drug development services; inspection of pharmaceuticals; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; consultancy relating to pharmaceutical research and development; pharmaceutical research and development; research on the subject of pharmaceuticals; clinical research in the field of medicine; consultancy pertaining to pharmacology; medical laboratories; medical research laboratory services; medical research laboratory services for predicting disease; medicine research; testing of pharmaceuticals

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, October 21, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGenexine, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressKR

Party NameGenexine, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR

Party NameGenexine, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Monday, March 18, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, February 27, 2024FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, February 27, 2024FINAL DISPOSITION PROCESSED
Wednesday, February 21, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, November 21, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, November 21, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, September 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 5, 2023PUBLISHED FOR OPPOSITION
Monday, September 4, 2023NOTIFICATION PROCESSED BY IB
Wednesday, August 16, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 16, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 16, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 28, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 13, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 13, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, June 13, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, June 13, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, June 13, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 13, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, February 8, 2023REFUSAL PROCESSED BY IB
Friday, January 13, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, January 13, 2023REFUSAL PROCESSED BY MPU
Thursday, November 3, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, November 2, 2022NON-FINAL ACTION WRITTEN
Wednesday, November 2, 2022ASSIGNED TO EXAMINER
Tuesday, October 25, 2022APPLICATION FILING RECEIPT MAILED
Friday, October 21, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 20, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB